Peer-reviewedCC BY 4.0OncoImmunology
A novel oncolytic peptide synergizing with immunotherapy
Abstract
In a recent paper published in Nature, Yuan et al. described an acid-responsive membranolytic peptide that temporally separates lysosomes from later plasma membrane rupture, thereby converting oncolysis into immunogenic cell death. This elegant design permits systemic administration, elicits antigen-specific immunity, and sensitizes tumors to programmed death ligand 1 blockade with remarkably limited toxicity.
Related
- A peptide-based nano-PROTAC synergistically driving ferroptosis-immunotherapy in triple-negative breast cancer
- OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer
- Editorial: Beyond conventional biomarkers: unlocking immunotherapy response through novel biomarkers or combinatorial approaches
- 524 Zopapogene imadenovec-drba, a novel adenovector-based immunotherapy, induces complete and durable responses in recurrent respiratory papillomatosis
- A novel CAF-related gene signature for prognostic and immunotherapy response prediction in PDAC based on single-cell RNA-seq and bulk RNA-seq data
BibTeX
@article{kroemer2026novel,
title = {{A novel oncolytic peptide synergizing with immunotherapy}},
author = {Guido Kroemer and Xiaolian Deng and Baldur Sveinbjørnsson and Oliver Kepp},
journal = {OncoImmunology},
year = {2026},
month = oct,
doi = {10.1080/2162402x.2026.2740845},
url = {https://hal.science/hal-05850589v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A novel oncolytic peptide synergizing with immunotherapy
AU - Guido Kroemer
AU - Xiaolian Deng
AU - Baldur Sveinbjørnsson
AU - Oliver Kepp
PY - 2026
DA - 2026/10/01
JO - OncoImmunology
DO - 10.1080/2162402x.2026.2740845
UR - https://hal.science/hal-05850589v1
AB - In a recent paper published in Nature, Yuan et al. described an acid-responsive membranolytic peptide that temporally separates lysosomes from later plasma membrane rupture, thereby converting oncolysis into immunogenic cell death. This elegant design permits systemic administration, elicits antigen-specific immunity, and sensitizes tumors to programmed death ligand 1 blockade with remarkably limited toxicity.
SN - 2162-4011
SN - 2162-402X
ER -